Endocannabinoids measurement in human Saliva as potential biomarker of obesity

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Matias, Isabelle ^a,b   Gatta Cherifi, Blandine ^a,b,c   Tabarin, Antoine ^a,b,c   Clark, Samantha ^a,b   Leste Lasserre, Thierry ^a,b   Marsicano, Giovanni ^a,b   Piazza, Pier Vincenzo ^a,b   Cota, Daniela ^a,b  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; INSULIN; MESSENGER RNA; N ACYLETHANOLAMINE DERIVATIVE; N OLEOYLETHANOLAMINE; PALMIDROL; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; ENDOCANNABINOID SALIVA LEVEL; ENZYME LOCALIZATION; FEMALE; FOOD INTAKE; HEALTH PROGRAM; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIQUID MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; METABOLIC REGULATION; N ACYLETHANOLAMINE DERIVATIVE SALIVA LEVEL; OBESITY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SALIVA ANALYSIS; SALIVA LEVEL; SALIVARY GLAND; TREATMENT DURATION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BASE SEQUENCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DNA PRIMERS; ENDOCANNABINOIDS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OBESITY; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVA;

EID: 84864444750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042399     Document Type: Article

References (44)

1. Bermudez-Silva FJ, Cardinal P, Cota D, (2012) The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 26: 114-124.
2. Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U, (2011) Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 17: 518-526.
3. Kunos G, Tam J, (2011) The case for peripheral CB receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163: 1423-1431.
4. Di Marzo V, Piscitelli F, Mechoulam R, (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol pp. 75-104.
5. Di Marzo V, Matias I, (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
6. Matias I, Bisogno T, Di Marzo V, (2006) Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 30 Suppl 1: S7-S12.
7. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, et al. (2007) Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 152: 676-690.
8. Cote M, Matias I, Lemieux I, Petrosino S, Alméras N, et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692-699.
9. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, et al. (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5: e8792.
10. Gatta-Cherifi B, Matias I, Vallee M, Tabarin A, Marsicano G, et al. (2012) Synergistic post-prandial deregulation of orexigenic and anorexigenic systems in obesity. Int J Obes (Lond) 36: 880-885.
11. Spielmann N, Wong DT, (2011) Saliva: diagnostics and therapeutic perspectives. Oral Dis 17: 345-354.
12. Lawrence HP, (2002) Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 68: 170-174.
13. Acosta A, Hurtado MD, Gorbatyuk O, La Sala M, Duncan D, et al. (2011) Salivary PYY: a putative bypass to satiety. PLoS One 6: e26137.
14. Li BB, Chen ZB, Li BC, Lin Q, Li XX, et al. (2011) Expression of ghrelin in human salivary glands and its levels in saliva and serum in Chinese obese children and adolescents. Arch Oral Biol 56: 389-394.
15. Benedix F, Westphal S, Patschke R, Granowski D, Luley C, et al. (2011) Weight loss and changes in salivary ghrelin and adiponectin: comparison between sleeve gastrectomy and Roux-en-Y gastric bypass and gastric banding. Obes Surg 21: 616-624.
16. Marczylo TH, Lam PM, Nallendran V, Taylor AH, Konje JC, (2009) A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. Anal Biochem 384: 106-113.
17. Lam PM, Marczylo TH, Konje JC, (2010) Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 398: 2089-2097.
18. Fezza F, Dillwith JW, Bisogno T, Tucker JS, Di Marzo V, et al. (2003) Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. Biochim Biophys Acta 1633: 61-67.
19. Prestifilippo JP, Fernandez-Solari J, Medina V, Rettori V, Elverdin JC, (2009) Role of the endocannabinoid system in ethanol-induced inhibition of salivary secretion. Alcohol Alcohol 44: 443-448.
20. Prestifilippo JP, Fernandez-Solari J, de la Cal C, Iribarne M, Suburo AM, et al. (2006) Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (Maywood) 231: 1421-1429.
21. Dall'Aglio C, Mercati F, Pascucci L, Boiti C, Pedini V, et al. (2010) Immunohistochemical localization of CB1 receptor in canine salivary glands. Vet Res Commun 34 Suppl 1: S9-12.
22. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ, (2003) Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102: 211-216.
23. Robson P, (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178: 107-115.
24. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, et al. (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781: 200-212.
25. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350.
26. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, et al. (2011) Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34: 2152-2157.
27. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180.
28. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N, (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298-5305.
29. Ueda N, Yamanaka K, Yamamoto S, (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276: 35552-35557.
30. Schwartz GJ, (2011) Gut fat sensing in the negative feedback control of energy balance-recent advances. Physiol Behav 104: 621-623.
31. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, et al. (2005) Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 62: 708-716.
32. Yoshida R, Ohkuri T, Jyotaki M, Yasuo T, Horio N, et al. (2010) Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci U S A 107: 935-939.
33. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, et al. (2008) The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8: 281-288.
34. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D, (2011) Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 108: 12904-12908.
35. Fernandez-Solari J, Prestifilippo JP, Ossola CA, Rettori V, Elverdin JC, (2010) Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. Arch Oral Biol 55: 583-590.
36. Modeer T, Blomberg CC, Wondimu B, Julihn A, Marcus C, (2010) Association between obesity, flow rate of whole saliva, and dental caries in adolescents. Obesity (Silver Spring) 18: 2367-2373.
37. Powers PS, Holland P, Miller C, Powers HP, (1982) Salivation patterns of obese and normal subjects. Int J Obes 6: 267-270.
38. Wooley OW, Wooley SC, Dunham RB, (1976) Deprivation, expectation and threat: effects on salivation in the obese and nonobese. Physiol Behav 17: 187-193.
39. Epstein LH, Paluch R, Coleman KJ, (1996) Differences in salivation to repeated food cues in obese and nonobese women. Psychosom Med 58: 160-164.
40. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843.
41. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, et al. (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52: 213-217.
42. Jumpertz R, Wiesner T, Bluher M, Engeli S, Bátkai S, et al. (2010) Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea-specific role of oleoylethanolamide. Exp Clin Endocrinol Diabetes 118: 591-595.
43. Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF, (2010) Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab (Lond) 7: 49.
44. Fanelli F, Di Lallo VD, Belluomo I, De Iasio R, Baccini M, et al. (2012) Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res 53: 481-493.